You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 15, 2026

Drug Price Trends for GNP POVIDONE-IODINE


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for GNP POVIDONE-IODINE

Average Pharmacy Cost for GNP POVIDONE-IODINE

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
GNP POVIDONE-IODINE 10% SOLN 24385-0053-55 0.01446 ML 2025-12-17
GNP POVIDONE-IODINE 10% SOLN 24385-0053-55 0.01416 ML 2025-11-19
GNP POVIDONE-IODINE 10% SOLN 24385-0053-55 0.01407 ML 2025-10-22
GNP POVIDONE-IODINE 10% SOLN 24385-0053-55 0.01394 ML 2025-09-17
GNP POVIDONE-IODINE 10% SOLN 24385-0053-55 0.01376 ML 2025-08-20
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Market Analysis and Price Projections for GNP Povidone-Iodine

Last updated: July 28, 2025


Introduction

GNP Povidone-Iodine, a broad-spectrum antiseptic, has seen sustained demand across healthcare, dental, and emergency sectors. Its utility in surgical preparations, wound management, and as a disinfectant underscores its significance within both developed and emerging markets. As a globally recognized branded generic, GNP Povidone-Iodine commands a notable market share due to its established efficacy and safety profile. This report offers an in-depth market analysis, including demand drivers, competitive landscape, regulatory framework, and price projections for GNP Povidone-Iodine over the upcoming five years.


Market Overview

Global Demand and Market Size

The global antiseptics market, valued at approximately USD 6.5 billion in 2022, exhibits a compound annual growth rate (CAGR) of around 4.2%. Povidone-iodine occupies a significant segment within this market, driven by its widespread use in preoperative skin disinfection, wound care, and microbial control. According to MarketsandMarkets, the antiseptics segment is projected to reach USD 9.4 billion by 2027, reflecting robust growth prospects.

In specific regional contexts, Asia-Pacific dominates demand owing to expanding healthcare infrastructure and heightened awareness about infection control. North America and Europe maintain substantial market shares attributable to mature healthcare systems and stringent infection prevention protocols. The anticipated growth is further fueled by rising surgical procedures and the global emphasis on infection control amid the COVID-19 pandemic.

Key Demand Drivers

  • Healthcare Infrastructure Expansion: Increasing investments in hospitals and clinics in emerging economies fuel demand for antiseptics.
  • COVID-19 Impact: Heightened hand hygiene awareness and sterilization practices resulted in sustained procurement of povidone-iodine products.
  • Regulatory Approvals: GNP Povidone-Iodine benefits from widespread regulatory acceptance, including approvals from FDA, EMA, and other health authorities.
  • Wound Care and Surgical Applications: Rising surgical volumes necessitate reliable antiseptic solutions, with povidone-iodine being a preferred choice for pre-op skin preparation.

Competitive Landscape

The market landscape is characterized by multiple multinational and regional players. Prominent brands include Betadine (MediNatura), Iso-Betadine (Mundipharma), and various generic manufacturers like GNP. GNP Povidone-Iodine competes based on brand reputation, formulation quality, supply chain stability, and pricing strategies.

Key Market Players

  • MediNatura (Betadine) — Leading market share through extensive distribution networks.
  • Mundipharma (Iso-Betadine) — Focuses on formulations for specific settings like surgical and wound care.
  • Regional Generics — Offer competitive pricing, particularly in emerging markets, leveraging local manufacturing.

GNP's market position hinges on quality assurance, cost-efficiency, and strategic distribution partnerships. Their capacity to adapt formulations (e.g., lower concentrations, liquid, ointment) enables market penetration across diverse healthcare settings.


Regulatory and Manufacturing Considerations

Regulatory approval processes influence market access and pricing strategies. GNP Povidone-Iodine benefits from established safety profiles, simplifying regulatory pathways in many jurisdictions. However, local regulations governing antiseptic formulations and labeling can vary, impacting market entry timelines and compliance costs.

Manufacturing capacity and supply chain resilience critically affect pricing. GNP’s manufacturing facilities situated in Asia and Europe position it advantageously to meet global demand while managing costs.


Pricing Dynamics

Current Pricing Landscape

Pricing varies regionally, affected by regulatory status, competitive positioning, and procurement channels. In developed markets, retail prices for a 500ml antiseptic solution range between USD 4-8, while generic versions are often priced lower.

In emerging markets, the price can be as low as USD 1-3 per bottle, driven by local manufacturing and procurement negotiations. GNP Povidone-Iodine’s pricing structures tend to be positioned competitively, balancing quality and cost efficiency.

Pricing Trends and Projections

Over the next five years, several factors influence pricing:

  • Market Saturation and Competition: Increased generic entry is likely to exert downward pressure on prices, especially in price-sensitive markets.
  • Regulatory and Market Access Costs: Stringent regulatory environments may increase costs, potentially creating pricing premiums.
  • Trade Policies and Tariffs: Changing international trade dynamics can impact import-export costs, influencing retail and wholesale prices.
  • Demand Elasticity: The essential nature of povidone-iodine ensures relatively inelastic demand, though price sensitivity varies regionally.

Projected Price Range (2023–2028):

Year Mean Price Range (USD per 500ml) Key Influences
2023 2.50 – 4.00 Competitive pressures; cost-effective manufacturing
2024 2.40 – 3.80 Intensified generic competition; broader regulatory compliance efforts
2025 2.20 – 3.60 Market saturation; procurement price negotiations
2026 2.10 – 3.50 Cost efficiencies; potential patent expiries in certain regions
2027 2.00 – 3.40 Increased regional manufacturing; bulk purchasing discounts
2028 1.90 – 3.30 Mature market saturation; focus on affordability

Regional Price Variations

Prices are expected to differ significantly across geographies:

  • North America and Europe: Retail prices maintain a premium, reflecting high regulatory standards, quality assurances, and distribution costs.
  • Asia-Pacific: Lower retail prices driven by local manufacturing, large-scale procurement, and price sensitivity.
  • Africa and Latin America: Prices affected by logistical challenges and lower purchasing power, positioning GNP formulations as affordable options.

Market and Price Outlook Summary

The global antiseptic market’s trajectory indicates steady growth, underpinned by increased healthcare expenditure and heightened infection control protocols. GNP Povidone-Iodine's established reputation supports its sustained demand. Price competition, regulatory adherence, and manufacturing efficiencies will shape its pricing landscape.

In the short to medium term, prices are projected to decline marginally due to market saturation and competitive pressures. However, GNP’s strategic positioning in emerging markets and ongoing product improvements could stabilize or even elevate certain premium segments.


Key Takeaways

  • GNP Povidone-Iodine remains a competitive player in a growing antiseptic market, sustained by its proven efficacy and regulatory acceptance.
  • Market growth is driven by healthcare infrastructure expansion, infection control needs, and global health initiatives.
  • Price projections suggest a gradual decline due to increased generic competition, with regional disparities creating differing price points.
  • Manufacturing and supply chain capabilities are critical to maintaining competitive pricing and market share.
  • Future regulatory changes and regional health policies could influence both demand and pricing strategies.

FAQs

1. What are the main factors influencing the pricing of GNP Povidone-Iodine?
Pricing is influenced by manufacturing costs, regional demand, regulatory requirements, competitive dynamics, and supply chain efficiencies.

2. How does GNP Povidone-Iodine compare to branded competitors like Betadine?
GNP Povidone-Iodine often competes on cost and availability, leveraging manufacturing efficiencies, while Betadine emphasizes brand reputation and global presence.

3. What are the growth prospects for GNP Povidone-Iodine in emerging markets?
These markets offer significant growth potential due to expanding healthcare infrastructure, increasing surgical procedures, and lower price sensitivity.

4. Are regulatory changes likely to impact the market for GNP Povidone-Iodine?
Yes. Stricter regulations and approval processes may increase compliance costs but could also serve as barriers for new entrants, benefiting established players like GNP.

5. How might the COVID-19 pandemic influence future demand and prices?
The pandemic has heightened awareness of infection control, leading to sustained demand. However, it may also result in supply chain disruptions, affecting prices temporarily.


References

[1] MarketsandMarkets. "Antiseptics Market by Product, Application, and Region — Global Forecast to 2027."
[2] Statista. "Global Healthcare Market Size and Trends."
[3] GlobalData. "Infection Control and Antiseptic Market Report."
[4] GNP Pharmaceutical Annual Reports and Product Catalogs.
[5] Regulatory Guidelines from FDA, EMA, and regional health authorities.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.